Development and Validation of a Nomogram Prognostic Model for SCLC Patients

Area of Science:

• Oncology
• Biostatistics
• Medical Informatics

Background:

• Small cell lung cancer (SCLC) constitutes approximately 15% of lung cancer diagnoses in the United States.
• Accurate prognostic models are crucial for risk stratification, treatment planning, and refining clinical trial eligibility criteria for SCLC patients.

Purpose of the Study:

• To develop and validate a novel nomogram prognostic model for patients with SCLC.
• To enhance the accuracy of prognostic predictions for SCLC beyond current AJCC TNM staging systems.

Main Methods:

• A nomogram model was developed using clinical data from 24,680 SCLC patients diagnosed between 2004 and 2011 (National Cancer Database).
• Independent validation was performed on a cohort of 9,700 SCLC patients diagnosed between 2012 and 2013.
• Prognostic performance was assessed using p-value, concordance index, and integrated area under the time-dependent receiver operating characteristic curve (AUC).

Main Results:

• The final prognostic model incorporated variables including age, sex, race, ethnicity, Charlson/Deyo score, TNM stage (AJCC 8th edition), treatment type, and laterality.
• The nomogram achieved a concordance index of 0.722 ± 0.004 and an integrated AUC of 0.79 in the validation cohort.
• The developed nomogram demonstrated significantly higher prognostic accuracy compared to previously established models, including the AJCC 8th edition TNM staging system.

Conclusions:

• A validated nomogram prognostic model for SCLC patients has been successfully developed.
• This novel nomogram offers improved prognostic accuracy for SCLC compared to existing staging methods.
• The nomogram has been implemented in an online webserver for broader accessibility and clinical utility.